You are posting a comment about...
Xiidra - New Medication for Dry Eye Disease
Recently, Shire pharmaceuticals released Xiidra to reduce the inflammatory component of chronic dry eye. More than 30 million Americans suffer with this painful condition. Xiidra, also called lifitegrast, is the first medication in over 16 years to be released and approved by the FDA to treat the signs and symptoms of dry eye disease. Patients with dry eye disease, DED, often have symptoms which range from blurred vision to painful eyes. Xiidra has been approved to not only improve the clinical signs of dry eye, but also to provide relief for these frustrating patient symptoms in as little as two weeks. The most common side effect of the medication is dysgeusiaâ€¦which is another way of saying most users have an unusual aftertaste.
While the medication can be costly, many insurance plans are adding Xiidra to their formulary and rebates are available to reduce patient co-pays. DED has many causes and for most patients, one treatment does not treat all signs and symptoms. We believe Xiidra will be an additive tool to improve our patients' long term ocular health and reduce the pain associated with chronic dry eye.
If you have any additional questions on this new medication, please call Rachel at 615-889-0147 to set up an appointment in our Dry Eye Clinic.